U.S. Markets closed

Synta Pharmaceuticals granted fast track designation for ganetespib

Synta Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track designation to the investigation of ganetespib improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen. FDA’s Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs that are intended to treat serious medical conditions and that demonstrate the potential to fill unmet medical needs.